Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

@article{Zintzaras2008InfliximabAM,
  title={Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.},
  author={Elias Zintzaras and Issa J. Dahabreh and Stavroula Giannouli and Michalis Voulgarelis and H M Moutsopoulos},
  journal={Clinical therapeutics},
  year={2008},
  volume={30 11},
  pages={1939-55}
}
BACKGROUND Because of its long-term effectiveness in clinical practice, methotrexate (MTX) is currently the preferred disease-modifying antirheumatic drug (DMARD) for patients with active rheumatoid arthritis (RRA). However, many patients do not experience remission and continue to have signs and symptoms of active disease while receiving a maximally tolerated dose. OBJECTIVES The aims of this meta-analysis were to estimate the efficacy and tolerability of the various dosage schemes of… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Because of its long - term effectiveness in clinical practice , methotrexate ( MTX ) is currently the preferred disease - modifying antirheumatic drug ( DMARD ) for patients with active rheumatoid arthritis ( RRA ) .
Infliximab and methotrexate in the treatment of rheumatoid arthritis : a systematic review and meta - analysis of dosage regimens . BACKGROUND .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
Mean patient age ranged from 44.6 to 56 years in the MTX - only arms and from 45.8 to 56 years in the infliximab + MTX arms .
Studies investigating infliximab + MTX regimens versus a control group receiving MTX alone to assess efficacy in active RA , using the American College of Rheumatology ( ACR ) criteria for 20% improvement ( ACR20 ) , 50% improvement ( ACR50 ) , and 70% improvement ( ACR70 ) , were considered eligible for the meta - analysis . Pooled odds ratios ( ORs ) and 95% CIs
Infliximab 3 mg / kkg + MTX was more effective than MTX alone ( OR = 3.52 [ 2.14 - 5.79 ] for reaching ACR20 ; 2.87 [ 2.228 - 3.61 ] for ACR50 ; and 2.42 [ 1.87 - 3.13 ] for ACR70 ) .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
Studies investigating infliximab + MTX regimens versus a control group receiving MTX alone to assess efficacy in active RA , using the American College of Rheumatology ( ACR ) criteria for 20% improvement ( ACR20 ) , 50% improvement ( ACR50 ) , and 70% improvement ( ACR70 ) , were considered eligible for the meta - analysis . Pooled odds ratios ( ORs ) and 95% CIs
Based on this meta - analysis , higher dose infliximab ( 10 mg / kg ) in combination with MTX appeared to be more effective than the standard 3 mg / kg dose , particularly for patients with severe disease activity .
were calculated to compare the relative risks and benefits of adding infliximab to MTX .
Infliximab 3 mg / kkg + MTX was more effective than MTX alone ( OR = 3.52 [ 2.14 - 5.79 ] for reaching ACR20 ; 2.87 [ 2.228 - 3.61 ] for ACR50 ; and 2.42 [ 1.87 - 3.13 ] for ACR70 ) .
Overall , 4899 patients were randomized to either infliximab + MTX ( 3919 patients ) or MTX alone ( 980 patients ) .
The proportion of female patients ranged from 66.6% to 100% in the MTX arms and from 68% to 100% in the infliximab arms .
Infliximab 10 mg / kkg + MTX was also more effective than MTX alone ( OR = 5.06 [ 3.88 - 6.59 ] for reaching ACR20 ; 5.72 [ 4.05 - 8.08 ] for ACR50 ; and 7.32 [ 2.28 - 23.50 ] for ACR70 ) .
Infliximab and methotrexate in the treatment of rheumatoid arthritis : a systematic review and meta - analysis of dosage regimens . BACKGROUND .
Overall , 4899 patients were randomized to either infliximab + MTX ( 3919 patients ) or MTX alone ( 980 patients ) .
Mean patient age ranged from 44.6 to 56 years in the MTX - only arms and from 45.8 to 56 years in the infliximab + MTX arms .
Infliximab 10 mg / kkg + MTX was also more effective than MTX alone ( OR = 5.06 [ 3.88 - 6.59 ] for reaching ACR20 ; 5.72 [ 4.05 - 8.08 ] for ACR50 ; and 7.32 [ 2.28 - 23.50 ] for ACR70 ) .
Mean patient age ranged from 44.6 to 56 years in the MTX - only arms and from 45.8 to 56 years in the infliximab + MTX arms .
Mean patient age ranged from 44.6 to 56 years in the MTX - only arms and from 45.8 to 56 years in the infliximab + MTX arms .
Infliximab 3 mg / kkg + MTX was more effective than MTX alone ( OR = 3.52 [ 2.14 - 5.79 ] for reaching ACR20 ; 2.87 [ 2.228 - 3.61 ] for ACR50 ; and 2.42 [ 1.87 - 3.13 ] for ACR70 ) .
Infliximab 3 mg / kkg + MTX was more effective than MTX alone ( OR = 3.52 [ 2.14 - 5.79 ] for reaching ACR20 ; 2.87 [ 2.228 - 3.61 ] for ACR50 ; and 2.42 [ 1.87 - 3.13 ] for ACR70 ) .
Overall , 4899 patients were randomized to either infliximab + MTX ( 3919 patients ) or MTX alone ( 980 patients ) .
Overall , 4899 patients were randomized to either infliximab + MTX ( 3919 patients ) or MTX alone ( 980 patients ) .
were calculated to compare the relative risks and benefits of adding infliximab to MTX .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
Infliximab and methotrexate in the treatment of rheumatoid arthritis : a systematic review and meta - analysis of dosage regimens . BACKGROUND .
Studies investigating infliximab + MTX regimens versus a control group receiving MTX alone to assess efficacy in active RA , using the American College of Rheumatology ( ACR ) criteria for 20% improvement ( ACR20 ) , 50% improvement ( ACR50 ) , and 70% improvement ( ACR70 ) , were considered eligible for the meta - analysis . Pooled odds ratios ( ORs ) and 95% CIs
Studies investigating infliximab + MTX regimens versus a control group receiving MTX alone to assess efficacy in active RA , using the American College of Rheumatology ( ACR ) criteria for 20% improvement ( ACR20 ) , 50% improvement ( ACR50 ) , and 70% improvement ( ACR70 ) , were considered eligible for the meta - analysis . Pooled odds ratios ( ORs ) and 95% CIs
Infliximab 10 mg / kkg + MTX was also more effective than MTX alone ( OR = 5.06 [ 3.88 - 6.59 ] for reaching ACR20 ; 5.72 [ 4.05 - 8.08 ] for ACR50 ; and 7.32 [ 2.28 - 23.50 ] for ACR70 ) .
Infliximab 10 mg / kkg + MTX was also more effective than MTX alone ( OR = 5.06 [ 3.88 - 6.59 ] for reaching ACR20 ; 5.72 [ 4.05 - 8.08 ] for ACR50 ; and 7.32 [ 2.28 - 23.50 ] for ACR70 ) .
Based on this meta - analysis , higher dose infliximab ( 10 mg / kg ) in combination with MTX appeared to be more effective than the standard 3 mg / kg dose , particularly for patients with severe disease activity .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
The aims of this meta - analysis were to estimate the efficacy and tolerability of the various dosage schemes of infliximab versus MTX for the treatment of active RA , to eliminate size - related uncertainty of effects , and to identify subgroups of patients who benefit most from infliximab + MTX therapy .
The proportion of female patients ranged from 66.6% to 100% in the MTX arms and from 68% to 100% in the infliximab arms .
All Topics